Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

PE-22-28.

Research draft

PE-22-28 is a shortened spadin-related experimental peptide.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

PE-22-28 is a shortened spadin-related experimental peptide.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It inhibits the TREK-1 potassium channel in laboratory systems.

Human research

A therapeutic human clinical evidence base was not established.

Preclinical & other research

Mouse and cell experiments investigated antidepressant-like responses and synaptic measures.

Safety & unknowns

Behavioural results in mice do not establish antidepressant efficacy or safety in people.

Regulatory status

Preclinical compound, not an established depression treatment.

Reported use & evidence

Research profile draft

The supplied PE-22-28 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds